MARKET

ARWR

ARWR

Arrowhead Pharma
NASDAQ
64.56
-0.44
-0.68%
After Hours: 65.00 +0.44 +0.68% 19:47 01/09 EST
OPEN
65.50
PREV CLOSE
65.00
HIGH
67.03
LOW
63.45
VOLUME
2.35M
TURNOVER
--
52 WEEK HIGH
76.76
52 WEEK LOW
9.57
MARKET CAP
8.77B
P/E (TTM)
-5291.8033
1D
5D
1M
3M
1Y
5Y
1D
How Investors May Respond To Arrowhead Pharmaceuticals (ARWR) China Approval Expanding REDEMPLO RNAi Metabolic Footprint
Simply Wall St · 23h ago
Arrowhead’s ARO-DIMERPA Trial Advances in Mixed Hyperlipidemia: What Investors Should Watch
TipRanks · 2d ago
Arrowhead Pharmaceuticals Launches Major Equity and Notes Offerings
TipRanks · 2d ago
BUZZ-U.S. STOCKS ON THE MOVE-Bloom Energy, Tyson Foods, Voyager Technologies
Reuters · 3d ago
BUZZ-Arrowhead Pharma rises after upsized $825 mln raise
Reuters · 3d ago
Assessing Arrowhead Pharmaceuticals (ARWR) Valuation After Obesity Trial Progress And New REDEMPLO Approvals
Simply Wall St · 3d ago
Arrowhead 3.1M share Secondary priced at $64.50
TipRanks · 3d ago
Arrowhead Pharmaceuticals prices upsize convertible notes offering to $625M and stock offering at $64.50
Seeking Alpha · 3d ago
More
About ARWR
Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The Company's Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, muscle and central nervous system. It has around 16 clinical-stage investigational medicines (wholly owned and partnered), which range in development stage from Phase I to Phase III. The Company's pipeline products include Plozasiran, Zodasiran, Olpasiran, ARO-RAGE, ARO-MMP7, GSK-4532990, Fazirsiran, GSK5637608, ARO-CFB, ARO-INHBE, ARO-C3, ARO-PNPLA3, ARO-DUX4, ARO-DM1 and ARO-ATXN2.

Webull offers Arrowhead Pharmaceuticals Inc stock information, including NASDAQ: ARWR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARWR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ARWR stock methods without spending real money on the virtual paper trading platform.